核素标记的抗Trop2单域抗体
By designing radionuclide-labeled anti-Trop2 single-domain antibodies, the problem of high expression and endocytosis of Trop2 protein in various epithelial malignant tumor cells was solved, achieving highly specific binding and endocytosis of Trop2 protein, thus improving the targeting and efficacy of tumor imaging and treatment.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- CHENGDU SHETAI MEDICAL TECH CO LTD
- Filing Date
- 2024-11-08
- Publication Date
- 2026-07-17
AI Technical Summary
In the existing technology, the use of Trop2 protein as a radionuclide marker for tumor targets has not been effectively addressed due to its high expression and endocytosis in various epithelial malignant tumor cells, resulting in poor tumor imaging and treatment effects.
We provide radionuclide-labeled anti-Trop2 single-domain antibodies, designed with complementary determinant regions and framework regions of specific amino acid sequences, to bind to the Fc region of immunoglobulins, achieving highly specific binding and endocytosis of Trop2 protein. These antibodies are then linked to radionuclides using chelating agents to form radionuclide-labeled antibodies for tumor imaging and treatment.
It achieves highly targeted uptake and long retention of Trop2-overexpressing tumors, improves the tumor/normal tissue ratio, and is suitable for early diagnosis, treatment, and risk stratification, with high imaging and therapeutic effects.
Smart Images
Figure CN119978125B_ABST